MaxCyte (MXCT)
(Delayed Data from NSDQ)
$2.04 USD
-0.02 (-0.97%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.05 +0.01 (0.49%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, MaxCyte, Inc. has a market cap of $219.22M, which represents its share price of $2.06 multiplied by its outstanding shares number of 106.42M. As a small-cap company, MXCT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
MXCT 2.04 -0.02(-0.97%)
Will MXCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MXCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MXCT
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
MXCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Other News for MXCT
MaxCyte (MXCT) Partners with Anocca AB in Licensing Deal
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell ...
MaxCyte announces strategic platform licensing agreement with Anocca AB
MaxCyte (MXCT) Receives "Overweight" Rating and New Price Target from Stephens & ...
MaxCyte (MXCT) Gains Overweight Rating with Promising Growth Outlook | MXCT Stock News